Meeting
2023 ASCO Annual Meeting
Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): A single-arm, phase II clinical trial.
Authors
Chunmei Bai
Peking Union Medical College Hospital, Beijing, China
Chunmei Bai , Chenyu Wang , Ning Jia , Xingming Chen , Xiaoli Zhu , Shuai Sun , Xiaohua Shi , Yu Chen , Yaping Luo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT04296747
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6070)
DOI
10.1200/JCO.2023.41.16_suppl.6070
Abstract #
6070
Poster Bd #
62
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Safety and efficacy of docetaxel combined with cisplatin as induction chemotherapy followed by cisplatin concurrent chemoradiotherapy plus gemcitabine as adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A prospective and multicenter phase II trial.
First Author: Zhi Hui Wang
Poster
2014 ASCO Annual Meeting
Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma.
First Author: Erminia Massarelli
Poster
2013 ASCO Annual Meeting
A randomized, multicenter, open phase II study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
First Author: Youngil Koh
Poster
2012 ASCO Annual Meeting
Phase II trial of chemoradiotherapy concurrent with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck (SCCHN): Results of the Japan Clinical Oncology Group study, JCOG 0706.
First Author: Makoto Tahara